🇮🇳IN
Sign In

Nippon India Taiwan Equity Fund- Direct Plan- Growth Option vs HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan

A side-by-side comparison of returns, cost, size and risk. These funds sit in DIFFERENT categories, so their returns are not directly comparable — they are exposed to different assets and risks.

NAV as of 17 Nov 2026. Returns over 1 year are annualised. Past performance does not indicate future returns, and this comparison is not a recommendation.

MetricNippon India Taiwan Equity FundHDFC Pharma and Healthcare Fund
CategoryThematic FundSectoral/ Thematic
Fund houseNippon India Mutual FundHDFC Mutual Fund
NAV₹24.9992₹23.411
1Y return+93.62%+15.90%
3Y return+57.04%+27.97%
5Y return——
AUM₹1,147 Cr₹3,501 Cr
Expense ratio1.07%1.05%
RiskVery HighVery High

Highlighting marks the higher return or lower cost on rows where both funds have data. It is arithmetic, not advice — a cheaper or higher-returning fund is not automatically the better choice for you.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer